A model measuring therapeutic inertia and the associated factors among diabetes patients: A nationwide population-based study in Taiwan

Journal of Clinical Pharmacology

Volumn 55, Issue 1, 2015, Pages 17-24

  Huang, Li Ying ^a,b   Shau, Wen Yi ^a   Yeh, Hseng Long ^c,d   Chen, Tsung Tai ^e   Hsieh, Jun Yi ^f   Su, Syi ^g   Lai, Mei Shu ^b  

^a Division of Health Technology Assessment Center for Drug Evaluation ^*  (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d CATHAY GENERAL HOSPITAL   (Taiwan)

^e FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^f UNIVERSITY OF TAIPEI   (Taiwan)

^g KAINAN UNIVERSITY   (Taiwan)

Author keywords

diabetes; HbA1c; healthcare providers; hierarchical linear model; therapeutic inertia

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; BUFORMIN; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIQUIDONE; GUAR GUM; HEMOGLOBIN A1C; INSULIN; METFORMIN; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONAMIDE; TOLAZAMIDE; UREA DERIVATIVE; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; CARDIOLOGIST; COHORT ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; ENDOCRINOLOGIST; FEMALE; GENERAL PRACTITIONER; HEALTH CARE PERSONNEL; HUMAN; INTERNIST; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; NEPHROLOGIST; OUTCOME ASSESSMENT; PHYSICIAN ATTITUDE; POPULATION RESEARCH; PRACTICE GUIDELINE; PRESCRIPTION; STATISTICAL MODEL; TAIWAN; BLOOD; CLINICAL PRACTICE; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; TAIWAN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84919717722     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.367     Document Type: Article

References (39)

1. International Diabetes Federation. IDF Diabetes Atlas. 5th ed. 2012. Available at: http://www.idf.org/diabetesatlas/5e/Update2012. Accessed March 27, 2013.
2. Teoh H, Home P, Leiter LA,. Should HBA1C targets be individualized for all people with diabetes? Arguments for and against. Diabetes Care. 2011; 34 (Suppl. 2): S191-S196.
3. Wild S, Roglic G, Green A, Sicree R, King H,. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27: 1047-1053.
4. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care. 2013; 36: S11-S66.
5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352: 854-865.
6. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321: 405-412.
7. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001; 135: 825-834.
8. Ziemer DC, Miller CD, Rhee MK, et al. Therapeutic inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ. 2005; 31: 564-571.
9. Grant R, Adams AS, Trinacty CM, et al. Relationship between patient medication adherence and subsequent therapeutic inertia in type 2 diabetes glycemic management. Diabetes Care. 2007; 30: 807-812.
10. Grant RW, Cagliero E, Dubey AK, et al. Therapeutic inertia in the management of Type 2 diabetes metabolic risk factors. Diabetes Med. 2004; 21: 150-155.
11. Berlowitz DR, Ash AS, Glickman M, et al. Developing a quality measure for therapeutic inertia in diabetes care. Health Serv Res. 2005; 40: 1836-1853.
12. O'Connor PJ, Sperl-Hillen JM, Johnson PE, Rush WA, Biltz G,. Therapeutic inertia and outpatient medical errors. April 2005. Agency for Healthcare Research and Quality. Available at: http://www.ahrq.gov/downloads/pub/advances/vol2/OConnor.pdf. Accessed September 1, 2013.
13. Chen TT, Chung KP, Lin IC, Lai MS,. The unintended consequence of diabetes mellitus pay-for-performance program in Taiwan: are patients with more comorbidities or more severe conditions likely to be excluded from the P4P program. Health Serv Res. 2011; 46: 47-60.
14. Lu FH, Yang YC, Wu JS, Wu CH, Chang CJ,. A population-based study of the prevalence and associated factors of diabetes mellitus in southern Taiwan. Diab Med. 1998; 15: 564-572.
15. Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY,. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc. 2005; 104: 157-163.
16. WHO Collaborating Center for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2012. Oslo, 2011. Available at: http://www.Whocc.No/filearchive/publications/2012-guidelines-with-front-pa.Pdf. Accessed March 27, 2013.
17. Meduru P, Helmer D, Rajan M, Tseng CL, Pogach L, Sambamoorthi U,. Chronic illness with complexity: implications for performance measurement of optimal glycemic control. J Gen Intern Med. 2007; 22 (Suppl. 3): 408-418.
18. Raudenbush SW, Bryk AS,. Hierarchical linear models: applications and data analysis methods. Thousand Oaks: Sage Publications; 2002.
19. Rosenzweig JL, Weinger K, Poirier-Solomon L, Rushton M,. Use of a disease severity index for evaluation of healthcare costs and management of comorbidities of patients with diabetes mellitus. Am J Manag Care. 2002; 8: 950-958.
20. Young GJ,. Can multi-level research help us design pay-for-performance programs? Med Care. 2008; 46: 109-111.
21. Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care. 2008; 14: 15-23.
22. Bingenheimer JB, Raudenbush SW,. Statistical and substantive inferences in public health: issues in the application of multilevel models. Annu Rev Public Health. 2004; 25: 53-77.
23. Diez-Roux AV,. Multilevel analysis in public health research. Annu Rev Public Health. 2000; 21: 171-192.
24. Huang LY, Yeh HL, Su S, Wang TC, Hsieh JY,. Estimating the influence of physicians on the underuse of drugs in diabetic nephropathy in Taiwan. J Nephrol. 2013; 26: 16-24.
25. Hicks PC, Westfall JM, Van Vorst RF, et al. Action or inaction? Decision making in patients with diabetes and elevated blood pressure in primary care. Diabetes Care. 2006; 29: 2580-2585.
26. Phillips LS, Ziemer DC, Doyle JP, et al. An endocrinologist-supported intervention aimed at providers improves diabetes management in a primary care site: improving primary care of African Americans with diabetes (IPCAAD) 7. Diabetes Care. 2005; 28: 2352-2360.
27. Bolen SD, Bricker E, Samuels TA, et al. Factors associated with intensification of oral diabetes medications in primary care provider-patient dyads: a cohort study. Diabetes Care. 2009; 32: 25-31.
28. Parchman ML, Pugh JA, Romero RL, Bowers KW,. Competing demands or therapeutic inertia: the case of elevated glycosylated hemoglobin. Ann Fam Med. 2007; 5: 196-201.
29. Oliveria SA, Lapuerta P, McCarthy BD, L'Italien GJ, Berlowitz DR, Asch SM,. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med. 2002; 162: 413-420.
30. Grol R,. Improving the quality of medical care: building bridges among professional pride, payer profit, and patient satisfaction. JAMA. 2001; 286: 2578-2585.
31. Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C,. Therapeutic inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care. 2005; 28: 600-606.
32. Ho Chan WS,. Taiwan's healthcare report 2010. EPMA J. 2010; 1: 563-585.
33. Huebschmann AG, Mizrahi T, Soenksen A, Beaty B, Denberg TD,. Reducing therapeutic inertia in hypertension treatment: a pragmatic randomized controlled trial. J Clin Hypertens (Greenwich). 2012; 14: 322-329.
34. Johnston C, Ponsonby E,. Northwest Herts diabetic management system. Comput Methods Programs Biomed. 2000; 62: 177-189.
35. Barnes CS, Ziemer DC, Miller CD, et al. There is little time for diabetes management in the primary care setting (IPCAAD 4). Diabetes Educ. 2004; 30: 126-135.
36. Hickling J, Rogers S, Nazareth I,. Barriers to detecting and treating hypercholesterolaemia in patients with ischaemic heart disease: primary care perceptions. Br J Gen Pract. 2005; 55: 534-538.
37. Doran T, Fullwood C, Reeves D, Gravelle H, Roland M,. Exclusion of patients from pay-for-performance targets by English physicians. N Engl J Med. 2008; 359: 274-284.
38. van Bruggen JA, Gorter KJ, Stolk RP, Rutten GE,. Shared and delegated systems are not quick remedies for improving diabetes care: a systematic review. Prim Care Diabetes. 2007; 1: 59-68.
39. van Bruggen R, Gorter K, Stolk R, Klungel O, Rutten G,. Therapeutic inertia in general practice: widespread and related to the outcome of diabetes care. Fam Pract. 2009; 26: 428-436.